Zama announces token staking details, will adopt liquid staking method
Foresight News reported that the Zama team has announced details of the ZAMA protocol staking mechanism. 60% of the rewards are allocated to KMS operators and their delegators, while 40% are distributed to co-processor operators and their delegators. Rewards are distributed based on the square root of the total stake of each operator, aiming to incentivize users to delegate to smaller operators. The maximum commission fee charged by operators is capped at 20%.
The Zama protocol adopts a Delegated Proof of Stake (DPoS) mechanism, currently featuring 18 active operators, including 13 Key Management Service (KMS) nodes and 5 Fully Homomorphic Encryption (FHE) co-processor nodes. Staking rewards come from protocol inflation, initially set at 5% of the total ZAMA supply per year.
After staking ZAMA, users will receive liquid staking shares representing their positions. Unstaking has a 7-day unbonding period, or users can exit quickly by transferring/selling their liquid staking shares. The first batch of operators includes institutions such as Artifact, Luganodes, Etherscan, Fireblocks, Ledger, and LayerZero.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS is bullish on CoreWeave (CRWV.US): Initiates "Buy" rating, betting on the return of AI trading rotation.
UBS has initiated coverage of the emerging cloud service provider CoreWeave (CRWV.US) with a "Buy" rating and set a target price of $120.
Sixth increase in six years! Disney(DIS.US) raises the monthly fee for Disney+ ad-free version by 13% to $21.49.
Walt Disney Company (DIS.US) is raising subscription prices for several of its streaming services in the U.S. market, marking the sixth price increase in six years, as the company aims to boost the profitability of its streaming business, which is crucial for Disney's future.
Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth
On September 24, according to the CDE website, Johnson & Johnson’s (JNJ.US) talquetamab (Chinese brand name: Tuolike) is proposed to be included in priority review.

